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Abstract: BACKGROUND: Many patients with cancer do not disclose complementary medicine use
but want their physician’s advice on this matter. This study evaluated whether using blended learning
(e-learning plus a workshop) to train oncology physicians in providing advice on complementary and inte-
grative medicine (CIM) therapies to their patients with cancer, in addition to distributing an information
leaflet on reputable CIM websites, had different effects on patient-reported outcomes for the consultation
than only distributing the leaflet. METHODS: In this multicenter, cluster-randomized trial, patients
from private practices/hospital departments, recruited by 48 oncology physicians randomly allocated to
an intervention group (CIM consultation plus information leaflet) or a control group (information leaflet),
received CIM information. Patient-reported outcomes included satisfaction (Patient Satisfaction With
Information on Cancer Treatment), readiness to make a decision (Preparation for Decision Making), and
physician-patient communication (European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire and Communication 26 [EORTC QLQ-COMU26]) for the consultation. Qualitative
interviews were conducted with a physician subsample. RESULTS: A total of 291 patients (128 in the
intervention group and 169 in the control group) advised by 41 physicians participated. Patients in the
intervention group rated physician-patient communication higher on all EORTC QLQ- COMU26 scales
(mean total score, 84.3 [95% CI, 79.5-89.2] vs 73.6 [95% CI, 69.3- 78.0]; P=.002), were more satisfied
with the advice (mean, 4.2 [95% CI, 4.0-4.4] vs 3.7 [95% CI, 3.5-3.8]; P<.001), and were readier to
make a decision (mean, 63.5 [95% CI, 57.4-69.6] vs 53.2 [95% CI, 47.8-58.7]; P= .016) than the con-
trol group. Physicians who reported patients in both settings seemed satisfied with the advice given.
CONCLUSIONS: This study evaluated a novel education intervention for training oncology physicians
in providing CIM advice in routine care. Providing structured CIM consultations had positive effects on
patient satisfaction, readiness to make decisions, and physician-patient communication.
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Effects of Training Oncology Physicians Advising Patients on 
Complementary and Integrative Therapies on Patient- Reported 
Outcomes: A Multicenter, Cluster- Randomized Trial
Alizé A. Rogge, BSc, BA, MSc 1; Stefanie M. Helmer, DrPH1,2; Ryan King, MSc1; Claudia Canella, MA3; Katja Icke1; 
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BACKGROUND: Many patients with cancer do not disclose complementary medicine use but want their physician’s advice on this  
matter. This study evaluated whether using blended learning (e- learning plus a workshop) to train oncology physicians in providing 
advice on complementary and integrative medicine (CIM) therapies to their patients with cancer, in addition to distributing an informa-
tion leaflet on reputable CIM websites, had different effects on patient- reported outcomes for the consultation than only distributing 
the leaflet. METHODS: In this multicenter, cluster- randomized trial, patients from private practices/hospital departments, recruited 
by 48 oncology physicians randomly allocated to an intervention group (CIM consultation plus information leaflet) or a control group 
 (information leaflet), received CIM information. Patient- reported outcomes included satisfaction (Patient Satisfaction With Information 
on Cancer Treatment), readiness to make a decision (Preparation for Decision Making), and physician- patient communication (European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire and Communication 26 [EORTC QLQ- COMU26]) for 
the consultation. Qualitative interviews were conducted with a physician subsample. RESULTS: A total of 291 patients (128 in the inter-
vention group and 169 in the control group) advised by 41 physicians participated. Patients in the intervention group rated physician- 
patient communication higher on all EORTC QLQ- COMU26 scales (mean total score, 84.3 [95% CI, 79.5- 89.2] vs 73.6 [95% CI, 69.3- 78.0]; 
P = .002), were more satisfied with the advice (mean, 4.2 [95% CI, 4.0- 4.4] vs 3.7 [95% CI, 3.5- 3.8]; P < .001), and were readier to make
a decision (mean, 63.5 [95% CI, 57.4- 69.6] vs 53.2 [95% CI, 47.8- 58.7]; P = .016) than the control group. Physicians who reported patients 
in both settings seemed satisfied with the advice given. CONCLUSIONS: This study evaluated a novel education intervention for train-
ing oncology physicians in providing CIM advice in routine care. Providing structured CIM consultations had positive effects on patient 
satisfaction, readiness to make decisions, and physician- patient communication. Cancer 2021;0:1-10. © 2021 American Cancer Society. 
KEYWORDS: cancer, clinical trials, complementary medicine, integrative oncology, physician- patient communication.
INTRODUCTION
Up to 70% of patients with cancer do not spontaneously disclose the use of complementary medicine (CM) therapies to 
their oncology physicians.1- 3 The reasons could include a perceived lack of knowledge and approval from the treating phy-
sician or the assumption that CM therapies are harmless and do not interfere with cancer treatment.4- 6 Clinical practice 
guidelines show that there is an emerging body of evidence for both beneficial and harmful interventions.7 Nevertheless, 
patients want to gain information from their oncology physicians on CM therapies8 and to receive support for decision- 
making.9,10 Because CM is not always part of cancer treatment, oncology physicians often do not give advice regarding 
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these therapies.11 Instead, patients might consult with 
nonmedical CM practitioners; hence, safety issues, such 
as adverse effects from CM12 or even the refusal of cancer 
treatment,13 can occur.
Integrating CM into cancer treatments could at its 
best result in an integrative oncology approach described 
as a “patient- centered, evidence- informed field of cancer 
care that utilizes mind and body practices, natural prod-
ucts, and/or lifestyle modifications from different tradi-
tions alongside conventional cancer treatments.”14
For this project, we used the term complemen-
tary and integrative medicine (CIM) because the train-
ing aims to enable oncology physicians to provide 
evidence- based advice but does not train them in the 
full set of competencies needed for an integrative on-
cology provider.15
Previous research has shown that patient- centered 
communication can influence patient satisfaction, 
decision- making, well- being, compliance with cancer 
therapy, and malpractice litigation.16,17 Numerous train-
ing programs for oncology physicians focusing on com-
munication18,19 or CIM20 coexist; however, the key to 
targeting the communication gap for CIM use in oncol-
ogy might be training that focuses on both communica-
tion and CIM.
The systematically developed Competence Network 
for Complementary Medicine– Consultation Training for 
Oncology Physicians (KOKON- KTO) training21 sup-
ports oncology physicians in providing evidence- based ad-
vice on CIM to their patients with cancer on the basis of 
a consultation manual that can be applied in routine care.
In clinical practice, the time that can be spent with 
a patient with cancer is limited. Therefore, it would be 
important to know whether a consultation that takes 20 
minutes and requires training is more beneficial than ad-
dressing the topic in 5 minutes on the basis of a leaflet 
about CIM websites. In the KOKON- KTO study, we 
evaluated whether training oncology physicians to give 
advice on CIM to their patients with cancer, in addition 
to distributing an information leaflet about reputable 
websites, had different effects on outcomes at the patient, 
physician, and physician- patient levels in comparison 
with only distributing the information leaflet.22 This arti-
cle focuses on the patient- reported outcomes.
MATERIALS AND METHODS
Design
In this prospective, multicenter, cluster- randomized, con-
trolled study, 48 oncology physicians were randomized 
by clusters (at the hospital department or private practice 
level) into an intervention group or a control group. The 
intervention group received the KOKON- KTO train-
ing21 (nine 45- minute e- learning modules and a 2- day 
onsite skill- training workshop), and the control group 
received only a short e- learning module (45 minutes) on 
how to distribute the KOKON- KTO information leaf-
let for reputable CIM websites.22 Oncology physicians in 
both groups were asked to provide advice for up to 10 of 
their patients with cancer (1 consultation per patient and 
a maximum of 10 patients per oncology physician). Both 
oncology physicians and patients with cancer completed 
standardized questionnaires. Then, the oncology physi-
cians in the control group also received KOKON- KTO 
training and were asked to conduct consultations on the 
basis of the KOKON- KTO framework21 with up to 5 
 patients with cancer.
Patients completed baseline questionnaires before 
consultation with the oncology physician. Two weeks 
after their consultations, the patients received a second 
questionnaire.
Subsequently, qualitative interviews were con-
ducted with a subsample of oncology physicians 
who gave advice in both consultation settings. The 
study followed the usual guidelines for clinical trials 
(Declaration of Helsinki and International Conference 
on Harmonisation Good Clinical Practice where ap-
propriate) and was approved by the respective ethics 
committees. The heads of the participating hospitals, 
oncology physicians, and patients with cancer provided 
written informed consent to participate in the study. 
For further information on the study design, see the 
published study protocol.22 The whole project, includ-
ing the development of the KOKON- KTO frame-
work,21 the trial, and the maintenance, was guided by 
the RE- AIM implementation research framework.23
KOKON- KTO Training
KOKON- KTO training is an evidence- based, blended- 
learning program training oncology physicians to con-
duct CIM consultations with their patients with cancer 
in a practice- relevant timeframe of approximately 20 
minutes.21 The KOKON- KTO framework has been 
systematically developed and has been positively evalu-
ated with an implementation research framework,21 
and it addresses the core competencies for integrative 
oncology providers.15 It is based on the semistandard-
ized consultation manual, and the training consists of 
9 units, each 45 minutes in length, of e- learning con-
tent and 16 units of the skill- training workshop over 2 
days.21
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Eligibility Criteria
Oncology physicians
Oncology physicians (50% oncology gynecologists 
treating female malignancies, including breast cancer 
only, and 50% oncologists) were recruited from hos-
pital departments (in each case, 2 oncology physicians 
as clusters) and private practices (in each case, 1 oncol-
ogy physician) specializing in oncology as part of the 
KOKON- KTO study.22 Physicians were eligible if they 
fulfilled the following selection criteria: self- reported 
little knowledge of CIM, no previous structured train-
ing in CIM in the field of oncology, minimal experience 
in advising patients with cancer on CIM, the ability 
to participate in the onsite skill- training workshop, and 
good German language skills. Eligibility criteria were 
determined in a standardized telephone interview with 
oncology physicians (self- disclosure). The included on-
cology physicians either were board- certified oncology 
residents or were in residency training for oncology as 
a medical specialty and were treating their own patients 
with cancer in Germany.22
Patients
Patients were eligible if they met the following criteria: 
they were interested in receiving advice on CIM, they 
were 18 years old or older, they were diagnosed with 
cancer, they were being treated at a participating hos-
pital department or private practice, cancer treatment 
was planned or ongoing, and they had good German 
language skills. Patients with severe cognitive impair-
ments were excluded by the participating oncology 
physicians.22
Randomization and Masking
Cluster randomization occurred at the physician level 
(level I, hospital department [2 oncology physicians per 
hospital] or private practice [1 oncology physician per 
private practice]; level II, specialization in oncology gy-
necology or oncology) with an allocation ratio of 1:1 
according to a first- come, first- served principle for both 
strata. The randomization list was generated by a statisti-
cian not otherwise involved in the study with SAS soft-
ware (version 9.4; SAS Institute, Cary, North Carolina). 
Patients were blinded to group assignments and recruited 
by participating oncology physicians. All of the patients 
were in treatment by the consulting oncology physician 
and hence knew the cancer treatment team and private 
practice/hospital department. However, because of the 
different training settings in both groups, the participat-
ing oncology physicians were not blinded.
Procedures
Intervention procedures
Patients with cancer in the intervention group received 
a 20- minute KOKON- KTO consultation by their treat-
ing oncology physician in addition to the KOKON- KTO 
 information leaflet describing 4 reputable CIM  websites.22 
The KOKON- KTO consultation was developed to train 
oncology physicians in giving advice on CIM to their 
 patients with cancer.21
Control procedures
Patients with cancer in the control group received 
a 5- minute consultation introducing the KOKON- 
KTO information leaflet by their treating oncology 
physician. No additional advice on CIM therapies was 
provided.
Physicians in both groups received the same 
 e- learning (including a example sentence and example 
video) for distributing the information leaflet. While 
handing out the flyer, physicians were trained to intro-
duce only the websites and not to go into specifics about 
CM therapies. More detailed information on the flyer is 
described in the KOKON- KTO study protocol.22
Patients with cancer in both groups were asked to 
complete the baseline assessments before the consultation 
with the oncology physician and further questionnaires 
2 weeks after the consultation. CIM consultations or the 
distribution of the information leaflet was included in the 
routine care visits.
Information about the KOKON- KTO study was 
displayed via flyers in hospital departments or in the re-
ception areas of private practices. Patients with cancer 
interested in receiving information about CIM then in-
dicated their interest in participating and were recruited 
according to a first- come, first- served principle.
Quantitative Outcomes and Outcome Measures
Outcomes and outcome measurements were based on a 
literature search and an expert consensus procedure.24 
Patients completed questionnaires on the quality of com-
munication (European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire and 
Communication 26 [EORTC QLQ- COMU26]25), their 
satisfaction with the CIM information provided during 
the consultation (Patient Satisfaction With Information 
on Cancer Treatment [PS- CaTE]26), and their prepara-
tion to make a decision about CIM (Preparation for 
Decision Making [PrepDM]27) 2 weeks after the consul-
tation with the oncology physician.
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Baseline Characteristics and Other Variables
At the baseline, patients documented sociodemographic 
data (eg, age, sex, and education), previous use of CIM 
therapies, and assumptions about their effectiveness 
(positive, neutral, or negative). Moreover, patients were 
asked to answer questions on their level of knowledge 
about CIM (multiple- choice questions based on 3 case 
vignettes; see the supporting information for CIM ques-
tions). Patients also rated their treating oncology physi-
cian’s empathy (Consultation and Relation Empathy 
Scale28) and their physician’s attitude toward CIM (self- 
developed instrument).
In addition, disease- specific information was doc-
umented by the oncology physician directly after the 
consultation.
Two weeks after the consultation, patients answered 
questions on the usefulness of the CIM websites provided 
by the KOKON- KTO information leaflet, answered the 
same multiple- choice questions on CIM knowledge that 
were asked at the baseline, and responded to questions 
about current and planned CIM use (and, in the case of 
current use, its effectiveness).
Statistical Analysis
Continuous variables are presented as means and standard 
deviations, and categorical variables are presented as abso-
lute and relative frequencies. The outcomes of the study 
were analyzed across all consultations (from a maximum 
of 10 consultations per oncology physician) via a linear 
mixed model with fixed effects: a control group effect, an 
intervention group effect, and the variables with which 
the randomization was stratified (hospital department/
private practice and oncology/gynecology). The cluster-
ing of patients within 1 oncology physician was included 
as a random effect. Patients who completed the follow- up 
questionnaires were analyzed for study purposes. Because 
all of the statistical analyses are considered exploratory, 
linear mixed model adjusted group means and 95% con-
fidence intervals (CIs) are displayed, and no sample size 
was calculated.22 Statistical analyses were conducted with 
RStudio software.29
Qualitative Data Collection and Analysis
The oncology physicians in the control group  received 
KOKON- KTO training after the intervention phase. 
After the KOKON- KTO skill- training workshop, on-
cology physicians were invited to conduct up to 5 
KOKON- KTO consultations with their patients on a 
voluntary basis because doing so was not part of the ini-
tial study agreement. In addition, to know more about 
their experiences with both settings, these physicians 
were invited for a qualitative telephone interview. After 9 
interviews, we seemed to have reached a saturated spec-
trum of expressed topics and experiences by the physi-
cians and subsequently stopped recruiting for more 
interview partners. In the qualitative interviews (see the 
supporting information for interview guidelines), oncol-
ogy physicians were asked about potential differences 
between the 2 consultation settings (KOKON- KTO 
consultation vs KOKON- KTO information leaflet only) 
in general and about differences in patient satisfaction 
with the advice given. Interviews occurred 8 to 10 weeks 
after the KOKON- KTO training. The interviews were 
audiotaped and transcribed verbatim. A qualitative con-
tent analysis was performed according to Flick30 and 
was supported by MAXQDA qualitative data analysis 
software.31 The transcripts were coded in content units 
combining deductive and inductive coding strategies. 
The research team predefined deductive codes accord-
ing to the KOKON- KTO consultation manual.21 Other 
subcategories were created in a continuous process of in-
ductively building and verifying codes from the data; this 
was accompanied by an intersubjective validation of the 
coding by 2 independent researchers (A.A.R. and C.C.) 
to verify the reliability and robustness of the data analy-
sis. In this article, concerning qualitative data, we focus 
on the reporting physicians’ perceptions of patients’ sat-
isfaction with both settings.
RESULTS
Patients with cancer received consultations between 
February 15, 2018, and November 30, 2018 (see Fig. 1  
for the Consolidated Standards of Reporting Trials study 
flow). In total, 291 patients (128 in the intervention 
group and 169 in the control group) received advice 
from 41 of the 48 randomized oncology physicians. Two- 
thirds of the patients were diagnosed with breast cancer 
or gynecological cancers. Oncology physicians in the con-
trol group treated patients with more severe tumors (see 
Table 1 for patients’ baseline data and Table 2 for physi-
cians’ baseline data).
Oncology physicians in the control group were 
slightly older, and there was a higher prevalence of 
women. They were also slightly more experienced 
working with patients with cancer than those in the 
 intervention group.
Patients with cancer (124 from the intervention 
group and 157 from the control group) answered fol-
low- up questionnaires 2 weeks after consultation with 
their oncology physician. No significant differences 
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in CIM knowledge or use between the patient groups 
were observed. However, the intervention group used 
slightly more CIM websites than the control group. 
Patients in the intervention group rated the consultation 
significantly higher on all EORTC QLQ- COMU2625 
scales (total score, 84.3 [95% CI, 79.5- 89.2] vs 73.6 
[95% CI, 69.3- 78.0]; P = .002). Oncology physicians 
who received the intervention seemed to be able to 
communicate better with respect to correcting misun-
derstandings (mean, 84.8 [95% CI, 79.6- 90.0] vs 71.5 
[95% CI, 66.9- 76.1]; P < .001) and showed better skills 
 related to the  information given (mean, 73.6 [95% CI, 
 67.4- 79.8] vs 58.3 [95% CI, 52.8- 63.8]; P < .001). The 
patients in the intervention group were more satisfied 
with the advice given (PS- CaTE26; mean, 4.2 [95% 
CI, 4.0- 4.4] vs 3.7 [95% CI, 3.5- 3.8]; P < .001). They 
also felt readier to make a decision (PrepDM27; mean, 
63.5 [95% CI, 57.4- 69.6] vs 53.2 [95% CI, 47.8- 58.7]; 
P =  .016; see Table 3 for the quantitative results) after 
the consultation.
Figure 1. Consolidated Standards of Reporting Trials study flow. KOKON- KTO indicates Competence Network for Complementary 
Medicine– Consultation Training for Oncology Physicians.
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A total of 9 oncology physicians in the control group 
were interviewed after they had provided consultations 
for patients in both settings (KOKON- KTO consultation 
vs information leaflet only).
Focusing on what the physicians perceived of the 
patients’ reactions in both settings, we found that the pre-
dominant topics identified from the interview data were 
the patients’ satisfaction and the perceived potential and 
TABLE 1. Patients’ Baseline Data
Characteristic
Intervention Group (n = 128),  
Mean ± SD or No. (%)
Control Group (n = 169), 
Mean ± SD or No. (%)
Sex: female 110 (85.9) 140 (82.8)
Age, y 54.1 ± 10.6 55.6 ± 11.8
Graduation level: A- level or higher 49 (38.3) 71 (42.0)
Cancer entities
Breast and gynecological 88 (68.8) 107 (63.3)
Gastrointestinal 13 (10.2) 26 (15.4)
Dermatological 2 (1.6) 0 (0)
Hematological 9 (7.0) 12 (7.1)
Ear, nose, and throat 4 (3.1) 2 (1.2)
Pulmonological 5 (3.9) 12 (7.1)
Sarcoma 1 (0.8) 1 (0.6)
Urological 0 (0) 1 (0.6)
Central nervous system 0 (0) 5 (3.0)
Other 6 (2.0) 2 (1.2)
Unknown 3 (1.0) 1 (0.6)
Tumor stage
T0 8 (8.1) 2 (1.6)
T1 33 (33.3) 37 (29.4)
T2 38 (38.4) 39 (31.0)
T3 15 (15.2) 29 (23.0)
T4 2 (2.0) 16 (12.7)
Tx 3 (3.0) 3 (2.4)
First diagnosis 93 (72.6) 122 (72.2)
Previous therapies
Surgery 86 (67.2) 101 (59.8)
Chemotherapy 94 (73.4) 114 (67.5)
Hormone therapy 21 (16.4) 29 (17.2)
Radiotherapy 53 (41.4) 49 (29.0)
Others 37 (28.9) 46 (27.2)
None 5 (3.9) 15 (8.9)
Previous CIM therapy: positive experience
Overall (at least 1 positive experience) 100 (78.1) 123 (72.8)
Acupuncture/acupressure 39 (30.5) 41 (24.3)
Anthroposophical medicine 6 (4.7) 12 (7.1)
Chinese herbs 4 (3.1) 8 (4.7)
Chiropractic 20 (15.6) 23 (13.6)
Homeopathy 54 (42.2) 68 (40.2)
Neural therapy 1 (0.8) 5 (3.0)
Osteopathy 29 (22.7) 34 (20.1)
Mistletoe 6 (4.7) 5 (3.0)
Other plant therapy 9 (7.0) 14 (8.3)
Qigong/tai chi 16 (12.5) 30 (17.8)
Yoga 32 (25.0) 33 (19.5)
Autogenic training 30 (23.4) 42 (24.9)
Progressive muscle relaxation 39 (30.5) 33 (19.5)
Others 17 (13.3) 17 (10.1)
Treatment objective
Curative/adjuvant 88 (68.8) 97 (57.4)
Palliative 34 (26.6) 68 (40.2)
Not clear 6 (4.7) 4 (2.4)
CIM knowledge
Example 1: correct answer 121 (94.5) 157 (94.6)
Example 2: correct answer 82 (64.6) 110 (65.9)
Example 3: correct answer 98 (77.8) 128 (76.2)
CAREa 45.8 ± 5.5 42.5 ± 7.6
Physician is open to CIMb 8.2 ± 2.4 7.5 ± 2.7
Abbreviations: CARE, Consultation and Relation Empathy Scale; CIM, complementary and integrative medicine; SD, standard deviation.
aHigher scores indicate higher empathy (10- 50).
bHigher scores indicate higher scores on openness toward CIM (1- 10).
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challenges of the 2 settings. Supplement 3 of the support-
ing information shows representative quotes from the 
interviewees.
From the physicians’ perspective, both patients 
with cancer receiving the information leaflet and 
 patients  receiving the KOKON- KTO consultation 
were satisfied with the information provided. Overall, 
patients from both groups seemed very grateful for their 
 physicians’ dedicating a considerable amount of their 
consultation time to discussing CIM. Patients receiving 
the KOKON- KTO consultation seemed to appreciate 
the opportunity to personally discuss the CIM possibil-
ities with their physician. However, patients with cancer 
in the control group welcomed the short consultation 
and seemed interested in exploring CIM websites. 
Although none of the patients with cancer explicitly 
expressed dissatisfaction with the short consultation, 2 
oncology physicians assumed that some patients might 
have expected more in- depth information and advice 
on CIM than only a leaflet. In particular, they agreed to 
participate in a respective scientific study. Some physi-
cians felt more connected to their patients when provid-
ing the KOKON- KTO consultation. However, patients 
with cancer also seemed satisfied with being referred to 
the information leaflet. Physicians reported that only a 
few patients asked for additional information and fur-
ther support for decision- making in favor of or against 
CIM for their specific individual conditions.
DISCUSSION
The results show that the structured consultation taught 
in the KOKON- KTO training had positive effects on 
physician- patient communication (EORTC QLQ- 
COMU26), readiness to make a decision about CIM 
(PrepDM), and patient satisfaction (PS- CaTE) in com-
parison with a setting in which patients with cancer re-
ceived only an information leaflet describing reputable 
CIM websites. To our knowledge, this study is the first 
evaluating blended learning training for oncology physi-
cians about advising patients with cancer on CIM in rou-
tine cancer care.
The research process was guided by an implemen-
tation research framework23 and started with framework 
development21 and the systematic definition of relevant 
patient- reported outcomes24; this was followed by the im-
plementation of the KOKON- KTO framework and its 
evaluation in a cluster- randomized trial and an in- depth 
qualitative analysis.22 Aspects of maintenance are cur-
rently being evaluated.
Although our training is scientifically founded and 
is now prepared for broad implementation, our study still 
has limitations when we consider the results at the patient 
level.
According to previous research,24 the definition 
of a single primary outcome based on the current state 
of scientific knowledge is not recommended when 
one is evaluating communication training programs 
in  oncology. Therefore, the main patient- reported 
outcomes of the KOKON- KTO study were defined 
on 3 different levels, including the patient level.22 
Because of the number of outcomes, the statistical 
tests were planned and judged in an exploratory man-
ner. Nevertheless, the results across all of the outcomes 
were homogeneous because they showed the positive 
effects of KOKON- KTO consultation in comparison 
with the information leaflet alone. Another limitation 
is that the “correct” implementation of the KOKON- 
KTO consultation manual (in accordance with the re-
spective KOKON- KTO framework21) was monitored 
only during the KOKON- KTO training. The ratings 
showed that all of the trained physicians were able to 
correctly implement it.21 However, there was no video 
recording of the physicians providing advice in actual 
routine care settings. The advantages and limitations 
of video recording were discussed when the study was 
being designed. On the basis of experience from a pre-
vious study32 in which video recording was performed, 
physicians gave feedback suggesting that video record-
ing negatively influenced the consultation; therefore, 
for this study, we decided to not use it.
In addition, this study measured only short- term 
outcomes; for future studies, it would be helpful to 
TABLE 2. Physicians’ Baseline Data
Characteristic
Intervention Group (n = 18),  
Mean ± SD or No. (%)
Control Group (n = 23), 
Mean ± SD or No. (%)
Age, y 40.5 ± 8.9 42.0 ± 10.6
Years working with cancer patients 11.0 ± 7.6 13.3 ± 10.7
Sex: female 14 (60.9) 19 (79.2)
Gynecology oncologist 11 (47.8) 12 (50.0)
Private practice 8 (34.8) 8 (33.3)
Abbreviation: SD, standard deviation.
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TABLE 3. Quantitative Results
IG (n = 122), Mean (95% CI) 
or No. (%)
CG (n = 154), Mean (95% CI) 
or No. (%)
IG- CG Difference, Mean (95% CI) 
or No. (%) P
EORTC- QLQ- COMU26a
Patient’s active role behaviors 85.0 (80.0 to 90.0) 74.3 (70.0 to 78.7) 10.7 (4.0 to 17.3) .003
Clinician- patient relationship 87.2 (82.1 to 92.4) 76.1 (71.5 to 80.7) 11.2 (4.2 to 18.1) .003
Professional’s qualities creating a 
relationship
89.6 (85.1 to 94.1) 80.8 (76.8 to 84.8) 8.8 (2.7 to 14.8) .006
Professional’s skills 90.3 (86.4 to 94.1) 84.5 (81.0 to 87.9) 5.8 (0.7 to 11.0) .029
Professional’s management of 
patient’s emotions
85.6 (80.7 to 90.5) 76.9 (72.5 to 81.2) 8.8 (2.2 to 15.3) .010
Professional takes into account 
patient’s preference
78.8 (71.8 to 85.9) 67.3 (61.1 to 73.5) 11.5 (2.1 to 20.9) .018
Professional corrects 
misunderstandings
84.8 (79.6 to 90.0) 71.5 (66.9 to 76.1) 13.3 (6.3 to 20.3) <.001
Professional’s skill related to 
information
73.6 (67.4 to 79.8) 58.3 (52.8 to 63.8) 15.3 (7.0 to 23.5) <.001
Enough privacy 85.0 (79.4 to 90.6) 74.0 (69.1 to 78.9) 11 (3.5 to 18.5) .006
Total score 84.3 (79.5 to 89.2) 73.6 (69.3 to 78.0) 10.7 (4.2 to 17.2) .002
PS- CaTEb 4.2 (4.0 to 4.4) 3.7 (3.5 to 3.8) 0.5 (0.2 to 0.8) <.001
PrepDMc 63.5 (57.4 to 69.6) 53.2 (47.8 to 58.7) 10.3 (2.1 to 18.4) .016
Usefulness of websites from the 
KOKON- KTO flyerd
Kokoninfo.de 7.1 (6.5 to 7.6) 6.5 (6.1 to 7.0) 0.5 (– 0.2 to 1.3) .143
Krebsinformationsdienst.de 6.9 (6.3 to 7.6) 7.0 (6.4 to 7.5) 0 (– 0.9 to 0.8) .927
Memorial Sloan Kettering 5.5 (4.2 to 6.9) 3.7 (2.6 to 4.8) 1.9 (0.1 to 3.6) .042
Onkopedia.com 6.8 (6.1 to 7.6) 6.5 (6.0 to 7.1) 0.3 (– 0.7 to 1.3) .522
CIM knowledge
Example 1: correct answer 120 (97.6) 147 (96.7)
Example 2: correct answer 90 (74.4) 97 (63.4)
Example 3: correct answer 98 (79.7) 116 (75.3)
CIM use (planned or currently used)
Acupuncture/acupressure 22 (18.0) 24 (15.6)
Anthroposophical medicine 4 (3.3) 6 (3.9)
Chinese herbs 4 (3.3) 6 (3.9)
Chiropractic 3 (2.5) 4 (2.6)
Homeopathy 28 (23.0) 49 (31.8)
Neural therapy 1 (1.2) 1 (0.6)
Osteopathy 9 (7.4) 21 (13.6)
Mistletoe 14 (11.5) 16 (10.4)
Other plant therapy 16 (13.1) 24 (15.6)
Qigong/tai chi 25 (20.5) 24 (15.6)
Yoga 52 (42.6) 42 (27.3)
Autogenic training 32 (26.2) 35 (22.7)
Progressive muscle relaxation 36 (29.5) 23 (14.9)
Others 34 (27.9) 35 (22.7)
Positive experience with current CIM 
therapy
Acupuncture/acupressure 3 (2.5) 8 (5.2)
Anthroposophical medicine 2 (1.6) 2 (1.3)
Chinese herbs 0 (0) 2 (1.3)
Chiropractic 2 (1.6) 2 (1.3)
Homeopathy 20 (16.4) 23 (14.9)
Neural therapy 0 (0) 0 (0)
Osteopathy 5 (4.1) 14 (9.1)
Mistletoe 4 (3.3) 2 (1.3)
Other plant therapy 8 (6.6) 8 (5.2)
Qigong/tai chi 8 (6.6) 13 (8.4)
Yoga 11 (9.0) 13 (8.4)
Autogenic training 9 (7.4) 14 (9.1)
Progressive muscle relaxation 12 (9.8) 11 (7.1)
Others 19 (15.6) 20 (13.0)
Abbreviations: CG, control group; CI, confidence interval; CIM, complementary and integrative medicine; EORTC- QLQ- COMU26, European Organisation 
for Research and Treatment of Cancer Quality of Life Questionnaire and Communication 26; IG, intervention group; KOKON- KTO, Competence Network for 
Complementary Medicine– Consultation Training for Oncology Physicians; PrepDM, Preparation for Decision Making; PS- CaTE, Patient Satisfaction With 
Information on Cancer Treatment.
aHigher scores indicate better communication (0- 100).
bHigher values indicate higher satisfaction (1- 5).
cHigher scores indicate higher perceived levels of preparation for decision- making (0- 100).
dHigher scores indicate higher ratings on the usefulness of websites (0- 10).
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evaluate long- term outcomes, such as CIM use, during 
the course of the disease.
The study compared 2 settings (KOKON- KTO 
consultation vs an information leaflet on CIM websites); 
interestingly, the physicians in both groups reported 
during the interviews that their patients seemed satis-
fied. However, the self- reported quantitative patient data 
showed much higher levels of satisfaction in the group 
that received the KOKON- KTO consultation. One ex-
planation might be that patients are reluctant to provide 
open feedback directly in consultations; this phenome-
non has been shown in other studies.33 On the basis of 
this outcome, the patient- reported data of this study 
might provide a more realistic picture. Adding qualitative 
data on the physicians’ view of patient satisfaction and 
comparing these data to the quantitative patient- reported 
outcomes showed an interesting gap, which might be an 
interesting aspect for future research, but more compara-
ble evaluation tools should be used. Time spent with the 
oncology physician in the consultation differed between 
the interventions (5 vs 20 minutes), and a question might 
arise regarding whether this finding explains the much 
higher level of satisfaction in the KOKON- KTO group. 
However, having more time in this context might not al-
ways result in better patient- physician interaction because 
previous research has shown that physicians without CIM 
training felt uneasy in such situations.34
Moreover, it is uncertain in what way the difference 
between the 2 groups in the cancer treatment objective 
(curative vs palliative) might have influenced study out-
comes because previous experiences, the type of cancer, 
expectations, and the social environment can also influ-
ence outcomes, and this makes it difficult to judge.
In summary, the results of the KOKON- KTO study 
at the patient level show that the consultation has a pos-
itive influence on patient satisfaction, physician- patient 
communication, and decision- making. As described in 
the literature, barriers to physician- patient communica-
tion persist and can have a negative influence on cancer 
treatment; however, physicians’ acceptance of patients’ 
interest in CIM and their knowledge of the safety and 
efficacy of these therapies might help to improve com-
munication about this topic.16,17 Oncology physicians 
addressing CIM with a structured approach could en-
hance patient satisfaction and improve patient adher-
ence to cancer treatments. A future directive might be 
to introduce a framework earlier in physicians’ medical 
training on how to advise patients with cancer on CIM 
(eg, in medical school). Additionally, the KOKON- KTO 
framework was developed as an evidence- based, system-
atic approach tailored to physicians’ and cancer patients’ 
needs; hence, in future initiatives, it could be interesting 
to explore whether this framework could be transferred to 
other health professions or disease areas.
In conclusion, this is the first study to implement 
and evaluate an evidence- based CIM consultation in 
routine cancer treatment. Advising patients with cancer 
according to a structured, evidence- based consultation 
manual showed positive effects on patient satisfaction, 
preparation for decision- making, and physician- patient 
communication in comparison with only distributing an 
information leaflet on CIM. The study results emphasize 
the importance of communication in physician- patient 
relationships. The implementation and application of 
the KOKON- KTO manual might lead to greater pa-
tient compliance and reporting of CIM use. Future 
studies should investigate whether the application of the 
KOKON- KTO consultation leads to changes in behavior 
(eg, use of CIM) in patients who are later than 4 weeks 
into the course of cancer treatment.
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